Mometasone furoate

Identification

Name
Mometasone furoate
Accession Number
DB14512
Description

Mometasone furoate is a corticosteroid drug that can be used for the treatment of asthma, rhinitis, and certain skin conditionsLabel10,11. It has a glucocorticoid receptor binding affinity 22 times stronger than dexamethasone and higher than many other corticosteroids as well2. Mometasone furoate is formulated as a dry powder inhaler, nasal spray, and ointment for its different indicationsLabel10,11.

Type
Small Molecule
Groups
Approved, Investigational, Vet approved
Structure
Thumb
Weight
Average: 521.429
Monoisotopic: 520.141944106
Chemical Formula
C27H30Cl2O6
Synonyms
  • Mometasone furoate
  • Mometasone furoate anhydrous
External IDs
  • SCH 32088
  • SCH-32088

Pharmacology

Indication

There are 3 formulations of mometasone furoate with various indications. The inhaler is indicated for prophylaxis of asthma in patients ≥4 yearsLabel. The nasal spray is indicated for treating nasal symptoms of allergic rhinitis in patients ≥2 years, treating symptoms of nasal congestion from seasonal allergic rhinitis in patients ≥2 years, treating nasal polyps in patients ≥18 years, and prophylaxis of seasonal allergic rhinitis in patients ≥12 years10. The ointment is indicated for symptomatic treatment of dermatitis and pruritis in patients ≥2 years11.

Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

Mometasone is a synthetic corticosteroid with an affinity for glucocorticoid receptors 22 times higher than that of dexamethasone2. Mometasone furoate also has a lower affinity to mineralocorticoid receptors than natural corticosteroids, making it more selective in its action2. Mometasone furoate diffuses across cell membranes to activate pathways responsible for reducing inflammationLabel1,2,3,10,11.

Mechanism of action

In asthma, mometasone is believed to inhibit mast cells, eosinophils, basophils, and lymphocytes3. There is also evidence of inhibition of histamine, leukotrienes, and cytokines3.

Corticosteroids diffuse across cell membranes into the cytosol of cells where they bind to glucocorticoid receptors to produce their activity2. Mometasone furoate has a particularly high receptor affinity compare to other corticosteroids, 22 times higher than that of dexamethasone2. Mometasone furoate binding to a glucocorticoid receptor causes conformational changes in the receptor, separation from chaperones, and the receptor moves to the nucleus3. Once at the nucleus, receptors dimerize and bind to a DNA sequence known as the glucocorticoid response element which either increases expression of anti-inflammatory molecules or inhibits expression of pro-inflammatory molecules (such as interleukins 4 and 5)3. Mometasone furoate also reduces inflammation by blocking transcription factors such as activator-protein-1 and nuclear factor kappa B (NF-kappaB)2,3.

TargetActionsOrganism
AGlucocorticoid receptorNot AvailableHumans
UProgesterone receptorNot AvailableHumans
Absorption

The mean time to peak concentration is 1.0 to 2.5 hoursLabel. Bioavailability has been reported as <1%Label but studies of repeat doses of inhaled corticosteroids suggest a bioavailability of 11%3. The 0.1% ointment may have a bioavailability of 0.7%11.

Volume of distribution

Steady state volume of distribution of 152LLabel.

Protein binding

98% to 99% (in vitro concentration of 5 to 500ng/mL)Label10.

Metabolism

Metabolism of mometasone furoate is largely performed hepatically by cytochrome P450 3A4 producing a number of metabolitesLabel10,1,3. Some of these metabolites include free mometasone and 6-beta-hydroxy-mometasone furoate1,3,4.

Hover over products below to view reaction partners

Route of elimination

For an inhaled dose, approximately 74% is excreted in the feces and 8% is excreted in the urineLabel10.

Half-life

The terminal half life of an inhaled dose is approximately 5 hoursLabel though it has been reported as 5.8 hours by other sources10,2.

Clearance

The clearance rate of mometasone furoate is not readily available1, though it may be close to 90L/h2.

Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity

Overdose with a mometasone furoate inhaler may occur with chronic overuseLabel10. Symptoms of chronic overuse may present as hypercorticism and adrenal suppression, and patients may not require any more treatment than monitoringLabel10.

In animal studies of pregnancy, some fetal toxic effects were seen at or above the maximum recommended human dose, though rodents are more sensitive to these effects than humansLabel10,11. The benefits and risks of use should be considered in pregnant patients10,11

It is unknown if mometasone furoate is excreted in breast milk but other corticosteroids are and therefore caution should be exercised when administering to nursing mothersLabel10,11.

Safety and effectiveness in pediatric populations has been established through clinical trials, though there may be a reduction in expected growth of about 1cm per year depending on the dose and duration of treatmentLabel. Pediatric patients should be titrated to the lowest effective dose for mometasone furoate inhalersLabel.

A trial of geriatric patients showed no difference in safety or efficacy compared to younger patients, however patients of an even greater age may still be more sensitive to mometasone furoateLabel10,11.

The use of a mometasone furoate inhaler in moderate or severe hepatic impairment rarely leads to detectable plasma concentrations though caution may be prudent with increasing degrees of severityLabel10.

The effects of mometasone furoate in renal impairment, and across gender and race have not been studiedLabel10.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbametapirThe serum concentration of Mometasone furoate can be increased when it is combined with Abametapir.
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Mometasone furoate.
AbirateroneThe metabolism of Abiraterone can be increased when combined with Mometasone furoate.
AcalabrutinibThe metabolism of Acalabrutinib can be increased when combined with Mometasone furoate.
AcarboseThe risk or severity of hyperglycemia can be increased when Mometasone furoate is combined with Acarbose.
AceclofenacThe risk or severity of gastrointestinal irritation can be increased when Mometasone furoate is combined with Aceclofenac.
AcemetacinThe risk or severity of gastrointestinal irritation can be increased when Mometasone furoate is combined with Acemetacin.
AcenocoumarolMometasone furoate may increase the anticoagulant activities of Acenocoumarol.
AcetohexamideThe risk or severity of hyperglycemia can be increased when Mometasone furoate is combined with Acetohexamide.
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Mometasone furoate is combined with Acetyldigitoxin.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
No interactions found.

Products

Product Ingredients
IngredientUNIICASInChI Key
Mometasone furoate monohydrateMTW0WEG809141646-00-6AQCCVUHZMIMSIB-HRVPQZBTSA-N
Active Moieties
NameKindUNIICASInChI Key
Mometasoneprodrug8HR4QJ6DW8105102-22-5QLIIKPVHVRXHRI-CXSFZGCWSA-N
International/Other Brands
Ecural (Essex pharma) / Elocom (Merck) / Elomet (Schering-Plough) / Eziwin (Intas) / mometAid (Progreś Laboratories) / Novasone (Schering-Plough)
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
AsmanexInhalant110 ug/1Respiratory (inhalation)Merck Sharp & Dohme Corp.2005-03-30Not applicableUS flag
AsmanexInhalant220 ug/1Respiratory (inhalation)Physicians Total Care, Inc.2006-03-09Not applicableUS flag
AsmanexInhalant220 ug/1Respiratory (inhalation)Merck Sharp & Dohme Corp.2005-03-30Not applicableUS flag
Asmanex HFAAerosol50 ug/1Respiratory (inhalation)Merck Sharp & Dohme Corp.2019-08-12Not applicableUS flag
Asmanex HFAAerosol200 ug/1Respiratory (inhalation)Merck Sharp & Dohme Corp.2014-04-25Not applicableUS flag
Asmanex HFAAerosol100 ug/1Respiratory (inhalation)Merck Sharp & Dohme Corp.2014-04-25Not applicableUS flag
Asmanex TwisthalerPowderRespiratory (inhalation)Merck Ltd.2011-12-21Not applicableCanada flag
Asmanex TwisthalerPowderRespiratory (inhalation)Merck Ltd.2011-12-21Not applicableCanada flag
Asmanex TwisthalerPowderRespiratory (inhalation)Merck Ltd.2015-04-08Not applicableCanada flag
Elocom CreamCreamTopicalMerck Ltd.1991-12-31Not applicableCanada flag
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Apo-mometasoneSpray, meteredNasalApotex Corporation2013-03-25Not applicableCanada flag
Mometasone FuroateLotion1 mg/1gTopicalImpax Generics2007-11-212017-06-01US flag
Mometasone FuroateOintment1 mg/1TopicalTorrent Pharmaceuticals Limited2018-07-13Not applicableUS flag
Mometasone FuroateOintment1 mg/1gTopicalPerrigo New York Inc2008-07-18Not applicableUS flag
Mometasone FuroateOintment1 mg/1gTopicalREMEDYREPACK INC.2017-05-122020-04-06US flag
Mometasone FuroateCream1 mg/1gTopicalNorthStar Rx LLC2019-09-17Not applicableUS flag
Mometasone FuroateOintment1 mg/1gTopicalREMEDYREPACK INC.2017-01-252020-03-31US flag
Mometasone FuroateSpray, metered50 ug/1NasalREMEDYREPACK INC.2018-03-202020-05-07US flag
Mometasone FuroateCream1 mg/1gTopicalSandoz2007-04-182014-09-30US flag
Mometasone FuroateOintment1 mg/1gTopicalGlenmark Pharmaceuticals Inc., USA2008-05-28Not applicableUS flag
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
MosaspraySpray, meteredNasalSandoz Canada Incorporated2016-06-172020-07-20Canada flag
Nasal Allergy and Congestion ReliefSpray, meteredNasalApotex CorporationNot applicableNot applicableCanada flag
Nasonex Allergy and CongestionSpray, meteredNasalMerck Ltd.Not applicableNot applicableCanada flag
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Atectura BreezhalerMometasone furoate (80 mcg) + Indacaterol (150 mcg)CapsuleRespiratory (inhalation)Novartis2020-08-19Not applicableCanada flag
Atectura BreezhalerMometasone furoate (160 mcg) + Indacaterol (150 mcg)CapsuleRespiratory (inhalation)Novartis2020-08-19Not applicableCanada flag
Atectura BreezhalerMometasone furoate (320 mcg) + Indacaterol (150 mcg)CapsuleRespiratory (inhalation)Novartis2020-08-19Not applicableCanada flag
DuleraMometasone furoate (200 ug/1) + Formoterol fumarate (5 ug/1)AerosolRespiratory (inhalation)A-S Medication Solutions2010-06-222018-09-30US flag
DuleraMometasone furoate (100 ug/1) + Formoterol fumarate (5 ug/1)AerosolRespiratory (inhalation)Merck Sharp & Dohme Corp.2010-06-22Not applicableUS flag
DuleraMometasone furoate (50 ug/1) + Formoterol fumarate (5 ug/1)AerosolRespiratory (inhalation)Merck Sharp & Dohme Corp.2019-08-12Not applicableUS flag
DuleraMometasone furoate (200 ug/1) + Formoterol fumarate (5 ug/1)AerosolRespiratory (inhalation)Merck Sharp & Dohme Corp.2010-06-22Not applicableUS flag
Enerzair BreezhalerMometasone furoate (160 mcg) + Glycopyrronium (50 mcg) + Indacaterol (150 mcg)CapsuleRespiratory (inhalation)NovartisNot applicableNot applicableCanada flag
QuinixilMometasone furoate (1 mg/1g) + Dimethicone (50 mg/1g)KitTopicalV2 Pharma, LLC2019-06-03Not applicableUS flag
QuinosoneMometasone furoate (1 mg/1g) + Ammonium lactate (120 mg/1g)KitTopicalV2 Pharma, LLC2019-06-03Not applicableUS flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Hyaluronic Acid Sodium Salt 2% / Mometasone Furoate 0.1% / Niacinamide 4%Mometasone furoate (0.1 g/100g) + Hyaluronic acid (2 g/100g) + Nicotinamide (4 g/100g)CreamTopicalSincerus Florida, LLC2019-05-21Not applicableUS flag

Categories

ATC Codes
D07AC13 — MometasoneR03BA07 — MometasoneD07XC03 — MometasoneR01AD09 — MometasoneR03AK09 — Formoterol and mometasone
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Pregnane steroids
Direct Parent
Gluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
Steroid esters / 20-oxosteroids / 11-beta-hydroxysteroids / 3-oxo delta-1,4-steroids / Halogenated steroids / Delta-1,4-steroids / Furoic acid esters / Alpha-chloroketones / Heteroaromatic compounds / Secondary alcohols
show 10 more
Substituents
11-beta-hydroxysteroid / 11-hydroxysteroid / 20-oxosteroid / 3-oxo-delta-1,4-steroid / 3-oxosteroid / 9-halo-steroid / Alcohol / Alkyl chloride / Alkyl halide / Alpha-chloroketone
show 30 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organochlorine compound, 11beta-hydroxy steroid, steroid ester, 20-oxo steroid, 3-oxo-Delta(1),Delta(4)-steroid, 2-furoate ester (CHEBI:47564)

Chemical Identifiers

UNII
04201GDN4R
CAS number
83919-23-7
InChI Key
WOFMFGQZHJDGCX-ZULDAHANSA-N
InChI
InChI=1S/C27H30Cl2O6/c1-15-11-19-18-7-6-16-12-17(30)8-9-24(16,2)26(18,29)21(31)13-25(19,3)27(15,22(32)14-28)35-23(33)20-5-4-10-34-20/h4-5,8-10,12,15,18-19,21,31H,6-7,11,13-14H2,1-3H3/t15-,18+,19+,21+,24+,25+,26+,27+/m1/s1
IUPAC Name
(1R,2R,3aS,3bS,9aS,9bR,10S,11aS)-9b-chloro-1-(2-chloroacetyl)-10-hydroxy-2,9a,11a-trimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl furan-2-carboxylate
SMILES

References

General References
  1. Szefler SJ: Pharmacokinetics of intranasal corticosteroids. J Allergy Clin Immunol. 2001 Jul;108(1 Suppl):S26-31. [PubMed:11449203]
  2. Hubner M, Hochhaus G, Derendorf H: Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunol Allergy Clin North Am. 2005 Aug;25(3):469-88. doi: 10.1016/j.iac.2005.05.004. [PubMed:16054538]
  3. Crim C, Pierre LN, Daley-Yates PT: A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. Clin Ther. 2001 Sep;23(9):1339-54. [PubMed:11589253]
  4. Teng XW, Cutler DJ, Davies NM: Mometasone furoate degradation and metabolism in human biological fluids and tissues. Biopharm Drug Dispos. 2003 Nov;24(8):321-33. doi: 10.1002/bdd.362. [PubMed:14595701]
  5. FDA Approved Drug Products: Asmanex Mometasone Furoate Inhalation Powder [Link]
  6. FDA Approved Drug Products: Nasonex Mometasone Furoate Nasal Spray [Link]
  7. FDA Approved Drug Products: Elocon Mometasone Furoate Lotion [Link]
  8. FDA Approved Drug Products: Sinuva Mometasone Furoate Sinus Implant [Link]
  9. FDA Approved Drug Products: Elocon Mometasone Furoate Ointment [Link]
  10. Mometasone Furoate Nasonex FDA Label [File]
  11. Mometasone Furoate Elocon FDA Label [File]
KEGG Drug
D00690
KEGG Compound
C07817
ChemSpider
390091
BindingDB
50148733
ChEBI
47564
ChEMBL
CHEMBL1161
ZINC
ZINC000003938677
PDBe Ligand
MOF
Wikipedia
Mometasone_furoate
AHFS Codes
  • 68:04.00 — Adrenals
  • 84:06.00 — Anti-inflammatory Agents
  • 52:08.08 — Corticosteroids
PDB Entries
1sr7 / 4e2j / 4p6w
FDA label
Download (609 KB)
MSDS
Download (185 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedNot AvailableAtopic Dermatitis (AD)1
4CompletedOtherRhinitis, Allergic, Perennial and Seasonal1
4CompletedTreatmentAdenoidal Hypertrophy1
4CompletedTreatmentAdenoids1
4CompletedTreatmentAllergic Rhinitis (AR)4
4CompletedTreatmentAllergic Rhinosinusitis / Chronic Eosinophilic Rhinosinusitis / Chronic Rhinosinusitis (Diagnosis)1
4CompletedTreatmentAsthma6
4CompletedTreatmentAsthma / Rhinitis, Allergic, Seasonal1
4CompletedTreatmentAsthma / Rhinitis / Sinusitis1
4CompletedTreatmentObstructive Sleep Apnea (OSA) / Perennial Allergic Rhinitis (PAR) / Sleep Disorder1

Pharmacoeconomics

Manufacturers
  • Schering corp sub schering plough corp
  • Altana inc
  • G and w laboratories inc
  • Glenmark generics inc usa
  • Taro pharmaceuticals usa inc
  • Tolmar inc
  • Nycomed us inc
  • Perrigo co
  • Perrigo new york inc
  • Schering corp
  • Schering plough healthcare products inc
  • Schering-Plough
Packagers
  • A-S Medication Solutions LLC
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Dixie Chem Tec Inc.
  • E. Fougera and Co.
  • G & W Labs
  • Glenmark Generics Ltd.
  • Harris Pharmaceutical Inc.
  • JSJ Pharmaceuticals Inc.
  • Lake Erie Medical and Surgical Supply
  • Nycomed Inc.
  • Perrigo Co.
  • Pharmedix
  • Physicians Total Care Inc.
  • Sandoz
  • Schering Corp.
  • Schering-Plough Inc.
  • Taro Pharmaceuticals USA
  • Tolmar Inc.
Dosage Forms
FormRouteStrength
CreamTopical0.05 g
InhalantRespiratory (inhalation)110 ug/1
InhalantRespiratory (inhalation)220 ug/1
AerosolRespiratory (inhalation)100 ug/1
AerosolRespiratory (inhalation)200 ug/1
AerosolRespiratory (inhalation)50 ug/1
Aerosol, powderRespiratory (inhalation)200 UG
Aerosol, powderRespiratory (inhalation)400 UG
PowderRespiratory (inhalation)
PowderRespiratory (inhalation)200 mcg/1dose
PowderRespiratory (inhalation)400 mcg/1dose
PowderRespiratory (inhalation)200 mcg
PowderRespiratory (inhalation)200 Mikrogramm
PowderRespiratory (inhalation)400 Mikrogramm
CapsuleRespiratory (inhalation)
Cream
Ointment
LotionTopical1.5 g
Cream0.1 %
Lotion0.1 %
Ointment0.1 %
SprayNasal0.05 %
CreamTopical1 g
CreamTopical0.1 g
LotionTopical0.1 g
Aerosol, meteredNasal0.05 %
AerosolRespiratory (inhalation)100 mcg
AerosolRespiratory (inhalation)200 mcg
AerosolRespiratory (inhalation)
CreamTopical1 mg/g
SolutionOral1 mg/g
Ointment1 mg/g
Ointment1 mg
CreamTopical1 mg/1g
OintmentTopical1 mg/1g
SolutionTopical
CreamTopical1 mg
CreamTopical0.1 %
LotionTopical0.1 %
OintmentTopical0.1 %
Cream100 mg/100g
SolutionTopical100 mg/100g
Lotion
SprayNasal
LotionTopical100 mg
SolutionTopical1 mg
SuspensionNasal; Respiratory (inhalation)50 cg
CreamTopical
EmulsionTopical0.1 g
PowderRespiratory (inhalation)2 mcg
Capsule; powderRespiratory (inhalation)2 mcg
PowderRespiratory (inhalation)4 mcg
Capsule; powderRespiratory (inhalation)4 mcg
Gel
PowderRespiratory (inhalation)400 mcg
Spray, suspensionNasal0.05 %
SolutionTopical1 mg/g
OintmentTopical1 mg/g
SprayNasal50 UG
SuspensionIntrasinal; Nasal50 mcg
SprayNasal50 Mikrogramm
CreamTopical100 mg
SuspensionIntrasinal; Respiratory (inhalation)0.05 g
CreamTopical1 g/100g
LotionTopical1 mg/1g
LotionTopical1 mg/1mL
OintmentTopical1 mg/1
SolutionTopical1 mg/1mL
SuspensionRespiratory (inhalation)0.05 g
SuspensionIntrasinal; Nasal0.05 g
Solution; sprayNasal0.05 %
EmulsionTopical1 mg/g
PowderRespiratory (inhalation)21.7 mcg
Aerosol, meteredRespiratory (inhalation)5 mcg
Spray, meteredNasal50 mcg
Spray, meteredNasal50 ug/1
Spray, suspensionNasal50 mcg/1dose
SprayNasal0.05 mg
Spray, meteredNasal
SprayNasal140 doz
LotionTopical
OintmentTopical
KitTopical
Suspension0.05 %
ImplantIntrasinal1350 ug/1
CreamTopical
CapsuleRespiratory (inhalation)18 mcg
CapsuleRespiratory (inhalation)9 mcg
Aerosol, meteredRespiratory (inhalation)
Aerosol, meteredRespiratory (inhalation)5 mcg/1dose
Prices
Unit descriptionCostUnit
Asmanex 120 Metered Doses 220 mcg/inh Aerosol 0.24 gm Inhaler230.27USD inhaler
Asmanex twisthaler 220 mcg #30131.47USD inhaler
Asmanex twisthaler 110 mcg #30121.76USD inhaler
Nasonex 50 mcg/act Suspension 50 mcg Nasal Spray116.82USD inhaler
Elocon 0.1% Lotion 60ml Bottle86.71USD bottle
Elocon 0.1% Cream 45 gm Tube79.13USD tube
Elocon 0.1% Ointment 45 gm Tube76.45USD tube
Mometasone Furoate 0.1% Solution 60ml Bottle64.99USD bottle
Mometasone Furoate 0.1% Cream 45 gm Tube50.96USD tube
Elocon 0.1% Lotion 30ml Bottle49.85USD bottle
Elocon 0.1% Ointment 15 gm Tube49.85USD tube
Elocon 0.1% Cream 15 gm Tube47.68USD tube
Mometasone Furoate 0.1% Ointment 45 gm Tube35.99USD tube
Mometasone Furoate 0.1% Solution 30ml Bottle32.99USD bottle
Mometasone Furoate 0.1% Cream 15 gm Tube29.99USD tube
Mometasone Furoate 0.1% Ointment 15 gm Tube19.19USD tube
Nasonex 50 mcg nasal spray6.37USD g
Elocon 0.1% cream2.69USD g
Mometasone furoate 0.1% cream1.42USD g
Elocom 0.1 % Cream0.7USD g
Elocom 0.1 % Ointment0.63USD g
Elocom 0.1 % Lotion0.47USD g
Pms-Mometasone 0.1 % Ointment0.35USD g
Ratio-Mometasone 0.1 % Ointment0.35USD g
Taro-Mometasone 0.1 % Ointment0.35USD g
Taro-Mometasone 0.1 % Lotion0.33USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US6127353Yes2000-10-032018-04-03US flag
US6240918Yes2001-06-052017-08-20US flag
US8173172Yes2012-05-082018-09-17US flag
US6503537Yes2003-01-072018-09-17US flag
US5829434Yes1998-11-032016-05-03US flag
US6068832No2000-05-302017-08-27US flag
US7067502Yes2006-06-272020-11-21US flag
US7566705Yes2009-07-282020-11-21US flag
US8109918No2012-02-072024-03-12US flag
US7951131No2011-05-312024-03-12US flag
US8025635No2011-09-272027-06-12US flag
US9585681No2017-03-072026-04-04US flag
US7951130No2011-05-312024-03-12US flag
US7544192No2009-06-092026-11-29US flag
US7951133No2011-05-312024-03-12US flag
US7713255No2010-05-112024-03-12US flag
US7662141No2010-02-162024-03-12US flag
US8763222No2014-07-012032-02-08US flag
US10232152No2019-03-192034-11-24US flag
US10406332No2019-09-102034-03-13US flag
US10357640No2019-07-232031-10-03US flag
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)215-228Not Available
water solubilityInsolubleNot Available
logP4.115Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0108 mg/mLALOGPS
logP4.27ALOGPS
logP5.06ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)13.84ChemAxon
pKa (Strongest Basic)-3.1ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area93.81 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity132.5 m3·mol-1ChemAxon
Polarizability52.31 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03mj-3891000000-64a4294ec7bf5ac82d6c

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Yes
General Function
Zinc ion binding
Specific Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name
NR3C1
Uniprot ID
P04150
Uniprot Name
Glucocorticoid receptor
Molecular Weight
85658.57 Da
References
  1. Isogai M, Shimizu H, Esumi Y, Terasawa T, Okada T, Sugeno K: Binding affinities of mometasone furoate and related compounds including its metabolites for the glucocorticoid receptor of rat skin tissue. J Steroid Biochem Mol Biol. 1993 Feb;44(2):141-5. [PubMed:8439518]
  2. Lumry WR: A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis. J Allergy Clin Immunol. 1999 Oct;104(4 Pt 1):S150-8. [PubMed:10518812]
  3. Smith CL, Kreutner W: In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneimittelforschung. 1998 Sep;48(9):956-60. [PubMed:9793625]
  4. Zhang X, Moilanen E, Adcock IM, Lindsay MA, Kankaanranta H: Divergent effect of mometasone on human eosinophil and neutrophil apoptosis. Life Sci. 2002 Aug 16;71(13):1523-34. [PubMed:12127907]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  6. Mometasone Furoate Twisthaler Label [File]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Progesterone receptor ...
Gene Name
PGR
Uniprot ID
P06401
Uniprot Name
Progesterone receptor
Molecular Weight
98979.96 Da
References
  1. Madauss KP, Deng SJ, Austin RJ, Lambert MH, McLay I, Pritchard J, Short SA, Stewart EL, Uings IJ, Williams SP: Progesterone receptor ligand binding pocket flexibility: crystal structures of the norethindrone and mometasone furoate complexes. J Med Chem. 2004 Jun 17;47(13):3381-7. [PubMed:15189034]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78. [PubMed:15601807]
  2. Backman JT, Filppula AM, Niemi M, Neuvonen PJ: Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. Pharmacol Rev. 2016 Jan;68(1):168-241. doi: 10.1124/pr.115.011411. [PubMed:26721703]
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Berger WE, Milgrom H, Chervinsky P, Noonan M, Weinstein SF, Lutsky BN, Staudinger H: Effects of treatment with mometasone furoate dry powder inhaler in children with persistent asthma. Ann Allergy Asthma Immunol. 2006 Nov;97(5):672-80. doi: 10.1016/S1081-1206(10)61099-X. [PubMed:17165278]
  2. Sharpe M, Jarvis B: Inhaled mometasone furoate: a review of its use in adults and adolescents with persistent asthma. Drugs. 2001;61(9):1325-50. [PubMed:11511026]
  3. Dvorak Z, Pavek P: Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35. doi: 10.3109/03602532.2010.484462. [PubMed:20482443]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Dvorak Z, Pavek P: Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35. doi: 10.3109/03602532.2010.484462. [PubMed:20482443]

Drug created on July 12, 2018 09:10 / Updated on October 21, 2020 01:55

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates